Navigation Links
Vaccine protects from deadly Hendra virus
Date:5/17/2011

CSIRO scientists have shown that a new experimental vaccine helps to protect horses against the deadly Hendra virus. Dr Deborah Middleton from CSIRO's Australian Animal Health Laboratory (AAHL) will announce the successful progress to develop the vaccine at the Australian Veterinary Association conference in Adelaide today.

"Our trials so far have shown that the vaccine prevents the infection of horses with Hendra virus," Dr Middleton said.

Stopping the disease in horses could also help protect people from the disease.

"A horse vaccine is crucial to breaking the cycle of Hendra virus transmission from flying foxes to horses and then to people, as it prevents both the horse developing the disease and passing it on," Dr Middleton said.

Hendra virus first appeared in 1994 and five of the 14 known outbreaks have spread to people. The virus has killed four of the seven people infected.

Depending on further development, field trials and registration the vaccine may be available as early as 2012.

Dr Barry Smyth, President of the Australian Veterinary Association, said that the news on the vaccine will be welcomed by both vets and horse owners.

"It's important that veterinarians and horse owners continue with precautions that reduce the risk of spreading the virus and that they report suspected cases immediately," Dr Smyth said. Recent work on evaluating the vaccine was jointly funded by the CSIRO, the Australian Government Department of Agriculture, Fisheries and Forestry and the Queensland Government Department of Employment, Economic Development and Innovation.

The development of the vaccine goes back more than ten years to shortly after CSIRO scientists first isolated the virus following the first outbreak of the disease in Hendra, Queensland.

Development and source of the vaccine is the result of a close collaboration with Dr Christopher Broder of the Uniformed Services University of the Health Sciences (the US federal health sciences university) supported by the US National Institutes of Health, but the high bio-containment facility at AAHL was essential for evaluating its beneficial effects.

"Our bio-security facility at AAHL is the only laboratory in the world where this work could have been done. It has been slow, painstaking and high-risk work and the credit is due to many people who've worked on this since 1994," Dr Middleton said.


'/>"/>

Contact: John Smith
John.M.Smith@csiro.au
61-732-142-960
CSIRO Australia
Source:Eurekalert

Related biology news :

1. Celiac disease vaccine shows promising results in Phase I trial
2. Study identifies promising target for AIDS vaccine
3. HIV protein unveils vaccine target
4. Allergy vaccine is nothing to sneeze at
5. Personlized dendritic cell vaccine increases survival in patients with deadly brain cancer
6. For first time, scientists show an HIV vaccine impacts the genetic makeup of the virus
7. Vaccine made with synthetic gene protects against deadly pneumonia
8. Media advisory -- Partnering to Fight TB: The Role of a TB Vaccine PDP
9. Saint Louis University findings: Dont pitch stockpiled avian flu vaccine
10. Researchers test inhalable measles vaccine
11. Therapeutic AIDS vaccine designed by HIVACAT reduces the viral load in the majority of AIDS patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2016)... Nearly one billion matches per second with DERMALOG,s high-speed AFIS    ... ... DERMALOG is Germany's largest Multi-Biometric supplier: The ... Identification Systems) ... Germany's largest Multi-Biometric supplier: The company's Fingerprint Identification System is part of ...
(Date:11/24/2016)... -- Cercacor today introduced Ember TM Sport Premium ... measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion Index, ... approximately 30 seconds. Smaller than a smartphone, using only ... key data about their bodies to help monitor these ... Hemoglobin carries oxygen to muscles. When hemoglobin and ...
(Date:11/22/2016)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce that the company has ... Sciences Awards as "Most Outstanding in eClinical Solutions" ... of recognition and growth for MedNet, which has effectively ... iMedNet ™ , MedNet,s flagship eClinical ...
Breaking Biology News(10 mins):
(Date:12/5/2016)... Atlanta, Georgia (PRWEB) , ... December 05, 2016 ... ... hydrophobic, lignin-coated nanocellulose, including both cellulose nanocrystals and cellulose nanofibrils. The composition ... nanocellulose. There are also claims directed to combination with polymers, carbon fibers, ...
(Date:12/5/2016)... 2016  Renova™ Therapeutics, a biotechnology company developing ... other chronic diseases, announced that Catherine Bovenizer ... Financial Officer (CFO), effective today. Ms. ... experience in financial management for a variety of ... Most recently, Ms. Bovenizer was the Vice President ...
(Date:12/5/2016)... , December 5, 2016 The ... with almost $108 billion of revenue and some $890 ... were spent on global biopharmaceuticals, and this figure is ... Stock-Callers.com has lined up these four equities for assessment: ... Pharmaceuticals Inc. (NASDAQ: ACAD ), Acorda Therapeutics ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... MA to soon resume cervical and lumbar disc production, company President, Jake Lubinski ... surgeons who are implanting the AxioMed disc in Bern, Lucerne, and Zurich to ...
Breaking Biology Technology: